Please ensure Javascript is enabled for purposes of website accessibility

Why These COVID-19 Vaccine Stocks Soared Today

By George Budwell – Apr 20, 2020 at 4:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors piled in to COVID-19 vaccine plays today. Here's why.

What happened

The COVID-19 vaccine space was on fire today. As of the market close Monday, shares of Inovio Pharmaceuticals (INO -2.19%) were up by 9.6%, while Moderna (MRNA -0.04%) rose 10.3%. Novavax (NVAX -3.61%), meanwhile, blasted higher by a jaw-dropping 24.7%, and VBI Vaccines (VBIV -3.98%) posted a comparable 24.2% gain.

Although none of these companies released an update on their COVID-19 vaccine program today, investors appear to be piling into the group as a whole ahead of the first batch of trial data slated to emerge within the next month or so. The first company to develop a viable COVID-19 vaccine should enjoy an enormous financial windfall after all.  

A woman being injected with a vaccine at a doctor's office.

Image Source: Getty Images.

So what

The world is slowly waking up to the painful realization that the current pandemic, along with the harsh social distancing measures required to contain it, may not end until a viable vaccine comes to market. Gilead Sciences' (GILD 0.21%) promising antiviral medication remdesivir could turn out to be a much-needed backstop to speed up recoveries and lower the mortality rate among severe cases. But it's not a preventative measure.

What's more, Gilead won't be able to manufacture enough of the drug to service the entire globe. As such, one or more vaccines will be needed to stamp out the COVID-19 pandemic. Inovio, Moderna, Novavax, and VBI Vaccines are all hoping to be among the first to fill this gigantic medical need with their experimental vaccine candidates.  

Now what

Where do things stand on vaccine development? Moderna became the first company to launch a human trial for a COVID-19 vaccine candidate earlier this year. This vaccine, called mRNA-1273, could be ready for widespread public consumption by mid-2021. Inovio, for its part, is developing a DNA-based vaccine dubbed INO-4800. This vaccine reportedly entered an early stage trial earlier this month. Novavax recently announced that its COVID-19 candidate, NVX-CoV2373, should enter clinical trials by mid-May. VBI Vaccines, on the other hand, is eyeing a pan-coronavirus vaccine targeting COVID-19, MERS, and SARS. The company's vaccine candidate is expected to enter human trials later this year. 

Are any of these stocks worth buying as a COVID-19 vaccine play? The short answer is no. We don't have a great track record when it comes to developing vaccines against coronavirus infections in humans. That doesn't mean this herculean effort is destined to fail, but it does make it impossible to handicap which company has the best chance of crossing the finish line. In other words, investors should probably take a cautious approach with this highly unpredictable field right now. All of these speculative biotech stocks could quickly reverse course and give up all of these recent gains.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
$18.70 (-3.61%) $0.70
Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
$1.79 (-2.19%) $0.04
Moderna Inc. Stock Quote
Moderna Inc.
$125.62 (-0.04%) $0.05
VBI Vaccines Stock Quote
VBI Vaccines
$0.72 (-3.98%) $0.03
Gilead Sciences Stock Quote
Gilead Sciences
$65.45 (0.21%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.